We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
So what does it take for a master perfumer to develop distinctive and classic scents? Yahoo Life Shopping delves into his thoughts, from ideation to getting his perfumes on the shelves. We also asked ...
Hosted on MSN
Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
Akero Therapeutics, Inc. (AKRO) closed the last trading session at $48.12, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across ...
We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against the other stocks ...
) has been revised to $64.26 / share. This is a decrease of 15.18% from the prior estimate of $75.76 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
On Monday, Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Akero Therapeutics, Inc. (AKRO) is a stock that can certainly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results